Drugs / Gadofosveset
Gadofosveset
also known as
gadofosveset trisodium · Ablavar · Gadofosveset (Ablavar/Vasovist) EMEA/H/C/000601 · MS-325
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00459446 | Apr 2007 → Nov 2008 | arterial occlusion, atherosclerosis, intermittent vascular claudication, peripheral arterial disease | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01600105 | Oct 2010 → Jul 2017 | liver disorder | Bachir Taouli | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT01609920 | May 2012 → May 2016 | breast neoplasm | Maastricht University Medical Center | Terminated | No outcome recorded |
| — | NCT01437865 | Sep 2011 → Feb 2012 | breast neoplasm | Maastricht University Medical Center | Completed | No outcome recorded |
| — | NCT01431300 | Aug 2011 → Jul 2012 | — | Duke University | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00375830 Background | Jan 2006 → Apr 2017 | cancer | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT02752191 Comparator | Apr 2016 → Dec 2018 | congenital heart disease | Paul Finn | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gadofosveset | “a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus)” NCT01600105 ↗ |
| Known as | Ablavar | “a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus)” NCT01600105 ↗ |
| Known as | Gadofosveset (Ablavar/Vasovist) EMEA/H/C/000601 | “Gadofosveset (Ablavar/Vasovist) EMEA/H/C/000601” NCT01437865 ↗ |
| Known as | gadofosveset trisodium | “a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus)” NCT01600105 ↗1“MS-325 Injection (Gadofosveset Trisodium)” NCT00459446 ↗ |
| Known as | MS-325 | “MS-325 Injection (Gadofosveset Trisodium)” NCT00459446 ↗ |
| Modality | Diagnostic / imaging agent | “A gadolinium-based contrast agent for MRI” NCT00375830 ↗ |
| Route | Other | “gadofosveset is injected” NCT00459446 ↗ |